- Location
combination therapy
"-
Chinese Anti-Malaria Drug Popular in Tanzania
Dec 29, 2015Young Masamba Issa has just clocked 13 years. The girl who almost lost her battle against malaria in 2008, is now a healthy five feet two inches tall form two student at Boko secondary school in Dar es Salaam. "I had given up when medical ...
Tags: Anti-Malaria Drug, Tanzania
-
BMS Received Breakthrough Therapy Designation for Its Investigational DCV Dual Regimen
Feb 26, 2014Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment ...
Tags: Bristol-Myers, Medicine
-
GlaxoSmithKline Says It Received a Positive Opinion in Europe for Albiglutide
Feb 10, 2014LONDON, Jan. 26 (UPI) -- GlaxoSmithKline says it received a positive opinion in Europe for albiglutide, under the brand name Eperzan, for treatment of type 2 diabetes. GSK officials said the Committee for Medicinal Products for Human Use ...
Tags: Albiglutide, Glaxosmithkline, FDA
-
FOB Synthesis and AstraZeneca Have Entered Into a Research and Development Option
Feb 7, 2014US-based FOB Synthesis and AstraZeneca have entered into a research and development option and license agreement for the development of a novel antibiotic for the treatment of drug-resistant bacterial infections. The new antibiotics will ...
Tags: FOB, BLI, AstraZeneca
-
An Anti-Malaria Drug Combination Might Prevent Pregnancy Complications in Women with Lupu
Jan 23, 2014An anti-malaria drug combination might be useful in helping to prevent pregnancy complications in women with lupus and the related disorder antiphospholipid syndrome, Yale School of Medicine researchers have found in a new study published ...
-
The U.S. Food and Drug Administration Approved Mekinist for Use with Another Drug
Jan 13, 2014The U.S. Food and Drug Administration on Friday approved Mekinist for use with another drug, Tafinlar, to treat advanced melanoma that is spreading or cannot be removed by surgery. Melanoma is the most deadly form of skin cancer, ...
-
FDA Approved Mekinist, or Trametinib, in Combination with Tafinlar
Jan 10, 2014The U.S. Food and Drug Administration approved Mekinist, or trametinib, in combination with Tafinlar, or dabrafenib, to treat patients with advanced melanoma. Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products ...
Tags: Skin Cancer, Health, Medicine
-
Two Drugs Might Be Better Than One When It Comes to Helping Hardcore Smokers Quit
Jan 9, 2014Two drugs in combination might be better than one when it comes to helping hardcore smokers quit, at least in the short term, a new study suggests. The drugs -- varenicline (sold under the brand name Chantix) and bupropion (Wellbutrin) ...
Tags: a
-
Women with Aggressive Breast Cancer Have a Slightly Improved Chance of Staying Cancer-Free
Dec 27, 2013Women with aggressive breast cancer who receive combination targeted therapy with chemotherapy prior to surgery have a slightly improved chance of staying cancer-free, researchers say. However, the improvement was not statistically ...
Tags: aggressive breast cancer, targeted therapy with chemotherapy
-
FDA Has Approved Sovaldi 400mg Tablets
Dec 10, 2013Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved Sovaldi (sofosbuvir) 400mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (CHC) infection ...
Tags: Gilead Sciences, Chronic Hepatitis
-
FDA Has Approved Janssen Therapeutics' NS3/4A Protease Inhibitor 'Olysio'
Nov 25, 2013The US Food and Drug Administration (FDA) has approved Janssen Therapeutics' NS3/4A protease inhibitor 'Olysio (simeprevir)' for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with ...
-
Advanced Proteome Therapeutics Has Announced The Achievement of an Important Milestone
Nov 12, 2013US-based Advanced Proteome Therapeutics has announced the achievement of an important milestone in its Cprogram with its collaborators by demonstrating that the first of a series of the company's site-specifically labeled protein conjugates ...
Tags: therapeutics, anti-cancer, proteome, Cprogram
-
Eli Lilly and Company Has Received Priority Review Status From The FDA
Oct 25, 2013Eli Lilly and Company has received priority review status from the US Food and Drug Administration (FDA) for its ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial ...
Tags: Cancer Drug, FDA Priority
-
AltheRx Pharmaceuticals Has Received a Notice of Allowance for Its Patent Application
Oct 21, 2013US-based clinical development firm AltheRx Pharmaceuticals has received a notice of allowance for its patent application from the US Patent and Trademark Office (USPTO) for the use of solabegron in combination with antimuscarinics at both ...
-
Amarin Announced Committee Has Voted 9 to 2 Against Approval of Vascepa Capsules for Use
Oct 18, 2013Amarin, a biopharmaceutical company, has announced the outcome of the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee for the use of Vascepa (icosapent ethyl) capsules in the treatment of high ...
Related Products
-
Remote Control Machine Electric Kneading and Heat Therapy Combination Foot Massager
-
Electric Shiatsu Remote Control Machine Kneading and Heat Therapy Combination Foot Massager
-
Vertical Pmst Infrared Light Therapy Combination Pmst Physio Magneto Machine
-
Portable Shockwave Tecar Therapy EMS 3 Technology Combination Physical Therapy Equipment
-
Super Laser Pmst Combination for Body Care Pain Relief Magnetic Therapy Physiotherapy
-
2 Pemf 2 Laser Handles Combination Emtt Therapy Physio Magnetic Therapy Machine
